Voss Capital LP increased its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 18.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,843,602 shares of the company's stock after acquiring an additional 603,602 shares during the period. Cellebrite DI comprises 5.7% of Voss Capital LP's investment portfolio, making the stock its 9th biggest holding. Voss Capital LP owned 1.61% of Cellebrite DI worth $74,681,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in CLBT. Axon Enterprise Inc. bought a new stake in Cellebrite DI during the 4th quarter worth approximately $198,270,000. Invesco Ltd. boosted its position in shares of Cellebrite DI by 122.1% during the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock valued at $64,043,000 after buying an additional 1,811,757 shares during the last quarter. Two Sigma Advisers LP grew its holdings in Cellebrite DI by 35.0% during the fourth quarter. Two Sigma Advisers LP now owns 1,811,100 shares of the company's stock worth $39,899,000 after buying an additional 470,000 shares in the last quarter. Handelsbanken Fonder AB raised its position in Cellebrite DI by 749.9% in the 1st quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock valued at $29,508,000 after buying an additional 1,340,000 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Cellebrite DI in the 1st quarter valued at $22,428,000. Institutional investors and hedge funds own 45.88% of the company's stock.
Cellebrite DI Stock Performance
CLBT stock traded up $0.20 during mid-day trading on Friday, hitting $16.11. The company had a trading volume of 1,663,790 shares, compared to its average volume of 2,261,916. The firm has a market cap of $3.86 billion, a PE ratio of -21.20, a price-to-earnings-growth ratio of 3.19 and a beta of 1.27. Cellebrite DI Ltd. has a 12 month low of $13.10 and a 12 month high of $26.30. The stock's fifty day moving average price is $14.95 and its two-hundred day moving average price is $17.47.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. During the same quarter last year, the business posted $0.10 EPS. Cellebrite DI's quarterly revenue was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on CLBT. Lake Street Capital reduced their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research note on Friday, August 15th. Wall Street Zen upgraded shares of Cellebrite DI from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. JPMorgan Chase & Co. reduced their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. Finally, Needham & Company LLC dropped their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $22.40.
Read Our Latest Stock Analysis on Cellebrite DI
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access